157 related articles for article (PubMed ID: 37156551)
21. Effector memory and central memory NY-ESO-1-specific re-directed T cells for treatment of multiple myeloma.
Schuberth PC; Jakka G; Jensen SM; Wadle A; Gautschi F; Haley D; Haile S; Mischo A; Held G; Thiel M; Tinguely M; Bifulco CB; Fox BA; Renner C; Petrausch U
Gene Ther; 2013 Apr; 20(4):386-95. PubMed ID: 22739387
[TBL] [Abstract][Full Text] [Related]
22. Development of a TCR-like antibody and chimeric antigen receptor against NY-ESO-1/HLA-A2 for cancer immunotherapy.
Liu X; Xu Y; Xiong W; Yin B; Huang Y; Chu J; Xing C; Qian C; Du Y; Duan T; Wang HY; Zhang N; Yu JS; An Z; Wang R
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35338087
[TBL] [Abstract][Full Text] [Related]
23. Enhancement of tumor-reactive cytotoxic CD4+ T cell responses after ipilimumab treatment in four advanced melanoma patients.
Kitano S; Tsuji T; Liu C; Hirschhorn-Cymerman D; Kyi C; Mu Z; Allison JP; Gnjatic S; Yuan JD; Wolchok JD
Cancer Immunol Res; 2013 Oct; 1(4):235-44. PubMed ID: 24396833
[TBL] [Abstract][Full Text] [Related]
24. Effective NY-ESO-1-specific MHC II-restricted T cell receptors from antigen-negative hosts enhance tumor regression.
Poncette L; Chen X; Lorenz FK; Blankenstein T
J Clin Invest; 2019 Jan; 129(1):324-335. PubMed ID: 30530988
[TBL] [Abstract][Full Text] [Related]
25. Phase 1 clinical trial to assess safety and efficacy of NY-ESO-1-specific TCR T cells in HLA-A∗02:01 patients with advanced soft tissue sarcoma.
Pan Q; Weng D; Liu J; Han Z; Ou Y; Xu B; Peng R; Que Y; Wen X; Yang J; Zhong S; Zeng L; Chen A; Gong H; Lin Y; Chen J; Ma K; Lau JYN; Li Y; Fan Z; Zhang X
Cell Rep Med; 2023 Aug; 4(8):101133. PubMed ID: 37586317
[TBL] [Abstract][Full Text] [Related]
26. Tumor-reactive CD8+ T-cell responses after vaccination with NY-ESO-1 peptide, CpG 7909 and Montanide ISA-51: association with survival.
Karbach J; Gnjatic S; Bender A; Neumann A; Weidmann E; Yuan J; Ferrara CA; Hoffmann E; Old LJ; Altorki NK; Jäger E
Int J Cancer; 2010 Feb; 126(4):909-18. PubMed ID: 19728336
[TBL] [Abstract][Full Text] [Related]
27. NY-ESO-1-specific redirected T cells with endogenous TCR knockdown mediate tumor response and cytokine release syndrome.
Ishihara M; Kitano S; Kageyama S; Miyahara Y; Yamamoto N; Kato H; Mishima H; Hattori H; Funakoshi T; Kojima T; Sasada T; Sato E; Okamoto S; Tomura D; Nukaya I; Chono H; Mineno J; Kairi MF; Diem Hoang Nguyen P; Simoni Y; Nardin A; Newell E; Fehlings M; Ikeda H; Watanabe T; Shiku H
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35768164
[TBL] [Abstract][Full Text] [Related]
28. Early disappearance of tumor antigen-reactive T cells from peripheral blood correlates with superior clinical outcomes in melanoma under anti-PD-1 therapy.
Bochem J; Zelba H; Spreuer J; Amaral T; Wagner NB; Gaissler A; Pop OT; Thiel K; Yurttas C; Soffel D; Forchhammer S; Sinnberg T; Niessner H; Meier F; Terheyden P; Königsrainer A; Garbe C; Flatz L; Pawelec G; Eigentler TK; Löffler MW; Weide B; Wistuba-Hamprecht K
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34933966
[TBL] [Abstract][Full Text] [Related]
29. A rare population of tumor antigen-specific CD4
Matsuzaki J; Tsuji T; Chodon T; Ryan C; Koya RC; Odunsi K
J Immunother Cancer; 2019 Jan; 7(1):7. PubMed ID: 30626427
[TBL] [Abstract][Full Text] [Related]
30. NY-ESO-1 antigen-reactive T cell receptors exhibit diverse therapeutic capability.
Sommermeyer D; Conrad H; Krönig H; Gelfort H; Bernhard H; Uckert W
Int J Cancer; 2013 Mar; 132(6):1360-7. PubMed ID: 22907642
[TBL] [Abstract][Full Text] [Related]
31. Human CLEC9A antibodies deliver NY-ESO-1 antigen to CD141
Masterman KA; Haigh OL; Tullett KM; Leal-Rojas IM; Walpole C; Pearson FE; Cebon J; Schmidt C; O'Brien L; Rosendahl N; Daraj G; Caminschi I; Gschweng EH; Hollis RP; Kohn DB; Lahoud MH; Radford KJ
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32737142
[TBL] [Abstract][Full Text] [Related]
32. CTLA-4 blockade increases antigen-specific CD8(+) T cells in prevaccinated patients with melanoma: three cases.
Yuan J; Ginsberg B; Page D; Li Y; Rasalan T; Gallardo HF; Xu Y; Adams S; Bhardwaj N; Busam K; Old LJ; Allison JP; Jungbluth A; Wolchok JD
Cancer Immunol Immunother; 2011 Aug; 60(8):1137-46. PubMed ID: 21465316
[TBL] [Abstract][Full Text] [Related]
33. Guillain-Barre syndrome observed with adoptive transfer of lymphocytes genetically engineered with an NY-ESO-1 reactive T-cell receptor.
Joseph J; Nathenson MJ; Trinh VA; Malik K; Nowell E; Carter K; Weathers SP; Demetri GD; Araujo D; Conley AP
J Immunother Cancer; 2019 Nov; 7(1):296. PubMed ID: 31703609
[TBL] [Abstract][Full Text] [Related]
34. NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives.
Thomas R; Al-Khadairi G; Roelands J; Hendrickx W; Dermime S; Bedognetti D; Decock J
Front Immunol; 2018; 9():947. PubMed ID: 29770138
[TBL] [Abstract][Full Text] [Related]
35. PD-1 is a regulator of NY-ESO-1-specific CD8+ T cell expansion in melanoma patients.
Fourcade J; Kudela P; Sun Z; Shen H; Land SR; Lenzner D; Guillaume P; Luescher IF; Sander C; Ferrone S; Kirkwood JM; Zarour HM
J Immunol; 2009 May; 182(9):5240-9. PubMed ID: 19380770
[TBL] [Abstract][Full Text] [Related]
36. Immune escape from NY-ESO-1-specific T-cell therapy via loss of heterozygosity in the MHC.
Klippel ZK; Chou J; Towlerton AM; Voong LN; Robbins P; Bensinger WI; Warren EH
Gene Ther; 2014 Mar; 21(3):337-42. PubMed ID: 24451117
[TBL] [Abstract][Full Text] [Related]
37. Persistent anti-NY-ESO-1-specific T cells and expression of differential biomarkers in a patient with metastatic gastric cancer benefiting from combined radioimmunotherapy treatment: a case report.
Merhi M; Raza A; Inchakalody VP; Siveen KS; Kumar D; Sahir F; Mestiri S; Hydrose S; Allahverdi N; Jalis M; Relecom A; Al Zaidan L; Hamid MSE; Mostafa M; Gul ARZ; Uddin S; Al Homsi M; Dermime S
J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32913031
[TBL] [Abstract][Full Text] [Related]
38. A phase 1 study of NY-ESO-1 vaccine + anti-CTLA4 antibody Ipilimumab (IPI) in patients with unresectable or metastatic melanoma.
Slingluff CL; Zarour HM; Tawbi HA; Kirkwood JM; Postow MA; Friedlander P; Devoe CE; Gaughan EM; Mauldin IS; Olson WC; Smith KT; Macri MJ; Ricciardi T; Ryan A; Venhaus R; Wolchok JD
Oncoimmunology; 2021 Mar; 10(1):1898105. PubMed ID: 33796406
[TBL] [Abstract][Full Text] [Related]
39. Tumor antigen-specific CD8
Lu X; Yang L; Yao D; Wu X; Li J; Liu X; Deng L; Huang C; Wang Y; Li D; Liu J
Cell Immunol; 2017 Mar; 313():43-51. PubMed ID: 28110884
[TBL] [Abstract][Full Text] [Related]
40. Recognition of NY-ESO-1+ tumor cells by engineered lymphocytes is enhanced by improved vector design and epigenetic modulation of tumor antigen expression.
Wargo JA; Robbins PF; Li Y; Zhao Y; El-Gamil M; Caragacianu D; Zheng Z; Hong JA; Downey S; Schrump DS; Rosenberg SA; Morgan RA
Cancer Immunol Immunother; 2009 Mar; 58(3):383-94. PubMed ID: 18677478
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
